News

PRESS RELEASE
Dr. Jeffrey S. Borer Urges Improved Drug Regulations to Ensure Heart Safety of Non-Heart Drugs

Current regulatory policies should be strengthened to ensure acceptable cardiovascular safety of drugs developed primarily for non-cardiovascular medical problems, according to a recent presentation made by Dr. Jeffrey Borer, an authority in cardiovascular medicine and surgery at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

His recommendations include earlier testing of all drugs' cardiovascular effects and giving regulatory bodies the authority to mandate continuing evaluation of drug effects, even after approval for marketing.

Read the full press release: Physician-Scientist Urges Improved Drug Regulation to Ensure Heart Safety of Non-Heart Drugs

PRESS RELEASE
Exercise Tolerance is Good Measure of Likely Progression of Mitral Regurgitation (MR)

A study from the Howard Gilman Institute of Valvular Heart Disease of Weill Cornell Medical College, headed by Dr. Jeffrey S. Borer, shows that exercise tolerance — determined by conventional exercise testing on a treadmill — is a good measure of likely progression to heart failure in patients with leaking mitral heart valves — mitral regurgitation (MR). The study was published in the October 15th issue of the American Journal of Cardiology.

Read the full press release: Excercise Tolerance is Good Measure of Likely Progression of Mitral Regurgitation (MR)

NEWSLETTER
Howard Gilman Institute for Valvular Heart Diseases (Nov. 2007)

Articles in the premiere issue of the Howard Gilman Institute for Valvular Heart Disease newsletter include:

• Director’s Column by Dr. Jeffrey S. Borer
• About the Institute’s Work
• Aortic valve disease:  Biopsy study evaluating the fundamental basis of heart dysfunction
• Diagnosing high blood pressure: 24-hour monitoring
• Dr. Jeffrey S. Borer in the News

Download full newsletter: November 2007